Zydus Lifesciences Limited

ZYDUSLIFE

INE010B01027

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 06:49:39 2025-01-17 am EST			5-day change	1st Jan Change
994.65 ^INR	+0.66%		-0.97%	+2.36%

Jan. 18	Zydus Lifesciences Receives Approval from USFDA to Conduct Phase II(B) Clinical Trial for Usnoflast	CI
Jan. 10	Nomura Upgrades Zydus Lifesciences to Buy From Neutral, Adjusts Price Target to INR1,140 From INR1,030	MT

Zydus Lifesciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024

November 12, 2024 at 02:05 am EST

Zydus Lifesciences Limited reported earnings results for the second quarter and six months ended September 30, 2024. For the second quarter, the company reported revenue was INR 53,052 million compared to INR 44,228 million a year ago. Net income was INR 9,112 million compared to INR 8,007 million a year ago. Basic earnings per share from continuing operations was INR 9.05 compared to INR 7.92 a year ago. Diluted earnings per share from continuing operations was INR 9.05 compared to INR 7.92 a year ago. Basic earnings per share was INR 9.06 compared to INR 7.91 a year ago. Diluted earnings per share was INR 9.06 compared to INR 7.91 a year ago.
For the six months, revenue was INR 115,759 million compared to INR 95,984 million a year ago. Net income was INR 23,311 million compared to INR 18,876 million a year ago. Basic earnings per share from continuing operations was INR 23.16 compared to INR 18.67 a year ago. Diluted earnings per share from continuing operations was INR 23.16 compared to INR 18.67 a year ago. Basic earnings per share was INR 23.17 compared to INR 18.65 a year ago. Diluted earnings per share was INR 23.17 compared to INR 18.65 a year ago.

Latest news about Zydus Lifesciences Limited

Zydus Lifesciences Receives Approval from USFDA to Conduct Phase II(B) Clinical Trial for Usnoflast	Jan. 18	CI
Nomura Upgrades Zydus Lifesciences to Buy From Neutral, Adjusts Price Target to INR1,140 From INR1,030	Jan. 10	MT
CVS Health Unit to Include Zydus Lifesciences' Diabetes Medications in Template Formulary	Jan. 07	MT
Zydus Announces Agreement with CVS Caremark to Add Zituvio Tm, Zituvimettm and Zituvimettm XR (Sitagliptin \| Sitagliptin and Metformin Hydrochloride) to Its Template Formulary	Jan. 06	CI
Zydus Lifesciences Limited Appoints Vikram Shukla as a President-Parenteral Operations	Jan. 03	CI
Zydus Lifesciences Gets Final Approval from US FDA for Lidocaine and Prilocaine Cream	Dec. 19	MT
Zydus Lifesciences Limited Receives Final Approval from USFDA for Lidocaine and Prilocaine Cream USP, 2.5%/2.5%	Dec. 19	CI
Zydus Lifesciences Limited Receives Demand Order-In-Original from Assistant Commissioner, Division Dehradun, Sector-7, Uttarakhand	Nov. 28	CI
Nomura Adjusts Zydus Lifesciences' Price Target to INR1,030 From INR1,020, Keeps at Neutral	Nov. 14	MT
Jefferies Adjusts Zydus Lifesciences' Price Target to INR1,380 From INR1,450, Keeps at Buy	Nov. 13	MT
Zydus Lifesciences Posts Gains in Fiscal Q2 Consolidated Net Profit	Nov. 13	MT
Zydus Lifesciences Limited, Q2 2025 Earnings Call, Nov 12, 2024	Nov. 12
India's Zydus Life posts Q2 profit rise on steady US demand	Nov. 12	RE
Zydus Lifesciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024	Nov. 12	CI
Zydus Lifesciences Limited Receives in Principle Acceptability from World Health Organization for Zyvac Tcv	24-10-23	CI
Zydus Lifesciences Limited Receives Final Approval from USFDA for Fludrocortisone Acetate Tablets USP, 0.1 Mg	24-10-17	CI
Zydus Lifesciences to Start Phase 2 Trials of Desidustat for Sickle Cell Disease	24-10-14	MT
Zydus Lifesciences Limited and ICMR Initiate A Phase 2 Proof-Of-Concept Trial of Desidustat in Patients with Sickle Cell Disease	24-10-14	CI
Zydus Lifesciences Limited Receives Final Approval from USFDA for Paliperidone Extended-Release Tablets	24-10-10	CI
Zydus Lifesciences Gets Tentative Nod from US FDA for Enzalutamide Tablets	24-10-02	MT
Zydus Receives Tentative Approval from USFDA for Enzalutamide Tablets, 40 Mg and 80 Mg	24-10-02	CI
Zydus Lifesciences Limited Receives Final Approval from USFDA for Enzalutamide Capsules, 40 Mg	24-09-28	CI
Zydus Lifesciences Limited and CSIR-Central Drug Research Institute Lucknow to Develop Best-In-Class Drug for Chronic Kidney Disease Induced Osteoporosis	24-09-27	CI
Zydus Lifesciences to Acquire Active Pharmaceutical Ingredients Business of Sterling Biotech	24-09-17	MT
Zydus Lifesciences Limited Receives Warning Letter from United States Food and Drug Administration	24-09-03	CI

Chart Zydus Lifesciences Limited

Duration

Period

ZYDUSLIFE: Dynamic Chart

Company Profile

Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations. Its product portfolio includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary, health, and wellness products. Its products include India formulations, Generics and Zydus biologics. The Company's products include Lipaglyn and Bilypsa (Saroglitazar), Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar) and Bryxta (Bevacizumab biosimilar). Its Zydus biologics covers various therapeutic areas, such as oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses, among others. The Company has a global presence and markets its products in the United States, India, Europe and emerging markets.

Employees

26,921

Sector

Pharmaceuticals

Calendar

2025-02-13 - Q3 2025 Earnings Release

More about the company